Intract Pharma

Intract Pharma Ltd specialises in creating oral therapeutics with optimised clinical efficacy. Intract’s oral formulation technologies are incorporated into several clinic stage products, one of which has passed a phase III trial and will be markets in 2019.

Intract utilises its specialist GI models to predict drug behaviour following oral dosing, and to ensure appropriate formulation dissolution characteristics in advance of preclinical and clinical analysis.

In 2017 Intract launched Soteria, an oral biologics delivery platform with protects biologic drugs and enhances permeation into GI tissue.